CHEK1 and cancer: The combination of cisplatin and olaparib in a small panel of lung cancer cell lines found cancer cell killing was achieved specifically in cells with low ERCC1 expression.[114] Mechanistic studies indicated that this combination leads to sustained DSBs, prolonged G2/M cell‐cycle arrest and the activation of Chk1 signalling with a significantly marked increase in apoptosis.